

Samir Parekh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2248198/publications.pdf>

Version: 2024-02-01

108
papers

4,361
citations

257450

24
h-index

123424

61
g-index

111
all docs

111
docs citations

111
times ranked

9757
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	3.5	43
2	Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 129-132.	0.4	1
3	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. <i>Cancer Cell</i> , 2022, 40, 441-443.	16.8	29
4	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
5	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
6	CD8+ T Cells: An ineffective armor against prolonged COVID-19 in cancer patients. <i>Cell Reports Medicine</i> , 2022, , 100695.	6.5	0
7	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 31-45.	2.2	7
8	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072098707.	2.5	10
9	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826.	4.1	9
10	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e470-e476.	0.4	12
11	Continuous genomic monitoring of multiple myeloma patients to identify patients of high risk for poor prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, e20035-e20035.	1.6	0
12	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 4652-4663.	7.0	6
13	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e975-e984.	0.4	5
14	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2981-2991.	1.3	2
15	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	16.8	176
16	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 599-613.	9.4	90
17	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1442-1444.	16.8	62
18	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	3

#	ARTICLE	IF	CITATIONS
19	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1601-1601.	1.4	0
20	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704.	1.4	6
21	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ixertinib-Treated Myeloma Patients. <i>Blood</i> , 2021, 138, 730-730.	1.4	4
22	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021, 7, eabg9551.	10.3	49
23	(Distinct) origins of IgM myeloma. <i>Blood</i> , 2021, 138, 1914-1915.	1.4	2
24	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. <i>Blood</i> , 2021, 138, 4720-4720.	1.4	0
25	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 326-326.	1.4	5
26	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021, 27, 2099-2103.	30.7	92
27	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. <i>Leukemia</i> , 2020, 34, 245-256.	7.2	38
28	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 450-464.	7.0	62
29	Discovery of a first-in-class EZH2 selective degrader. <i>Nature Chemical Biology</i> , 2020, 16, 214-222.	8.0	148
30	Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m ² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m ² . <i>American Journal of Hematology</i> , 2020, 95, E51-E54.	4.1	0
31	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 100, 3057-3060.	1.8	2
32	Where you live can impact your cancer risk: a look at multiple myeloma in New York City. <i>Annals of Epidemiology</i> , 2020, 48, 43-50.e4.	1.9	9
33	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94.	17.0	107
34	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958.	2.2	16
35	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020, 26, 1636-1643.	30.7	1,860
36	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 5895-5902.	7.0	25

#	ARTICLE	IF	CITATIONS
37	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2208-2215.	1.3	7
38	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751.	0.4	2
39	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e247-e255.	2.0	5
40	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1.	0.4	31
41	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. <i>Oncotarget</i> , 2020, 11, 727-739.	1.8	12
42	Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
43	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020, 136, 6-7.	1.4	8
44	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-13.	1.4	0
45	289â€¦PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
46	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
47	A Network Analysis of Multiple Myeloma Related Gene Signatures. <i>Cancers</i> , 2019, 11, 1452.	3.7	23
48	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. <i>Blood</i> , 2019, 134, 1779-1779.	1.4	1
49	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. <i>Blood</i> , 2019, 134, 3093-3093.	1.4	0
50	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. <i>Blood</i> , 2019, 134, 4384-4384.	1.4	0
51	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3101-3101.	1.4	2
52	SOX11 augments BCR signaling to drive MCL-like tumor development. <i>Blood</i> , 2018, 131, 2247-2255.	1.4	37
53	Targeting HSF1: A Prime Integrator of Proteotoxic Stress Response in Myeloma. <i>Clinical Cancer Research</i> , 2018, 24, 2237-2238.	7.0	3
54	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. <i>JCO Precision Oncology</i> , 2018, 2018, 1-17.	3.0	20

#	ARTICLE	IF	CITATIONS
55	Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 141-159.	1.6	9
56	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2616.	4.8	44
57	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. <i>Blood Advances</i> , 2018, 2, 1470-1479.	5.2	31
58	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. <i>Cell Stem Cell</i> , 2017, 20, 315-328.e7.	11.1	114
59	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. <i>Blood Advances</i> , 2017, 1, 1575-1583.	5.2	39
60	The effect of novel therapies in high-molecular-risk multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 870-879.	0.3	10
61	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. <i>Cancer Research</i> , 2016, 76, 1225-1236.	0.9	25
62	Inhibiting SOX11-DNA Interaction in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1840-1840.	1.4	2
63	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. <i>Blood</i> , 2016, 128, 3277-3277.	1.4	3
64	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. <i>Blood</i> , 2016, 128, 3448-3448.	1.4	1
65	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , 2016, 128, 4088-4088.	1.4	2
66	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4520-4520.	1.4	3
67	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. <i>Blood</i> , 2016, 128, 802-802.	1.4	1
68	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. <i>Blood</i> , 2016, 128, 3285-3285.	1.4	1
69	Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. <i>Blood</i> , 2016, 128, 357-357.	1.4	0
70	Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. <i>Blood</i> , 2016, 128, 4450-4450.	1.4	0
71	Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 293ra102.	12.4	43
72	Integrative network modeling approaches to personalized cancer medicine. <i>Personalized Medicine</i> , 2015, 12, 245-257.	1.5	12

#	ARTICLE	IF	CITATIONS
73	SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis. <i>Blood</i> , 2015, 126, 1253-1253.	1.4	1
74	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1434-1434.	1.4	6
75	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib. <i>Blood</i> , 2015, 126, 3051-3051.	1.4	2
76	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015, 126, 342-342.	1.4	14
77	Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab. <i>Blood</i> , 2015, 126, 3571-3571.	1.4	8
78	Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. <i>Blood</i> , 2015, 126, 4195-4195.	1.4	2
79	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. <i>Blood</i> , 2015, 126, 4226-4226.	1.4	14
80	Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. <i>Oncotarget</i> , 2015, 6, 27332-27342.	1.8	15
81	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1851-1851.	1.4	0
82	Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 840-840.	1.4	0
83	Adverse drug reaction: pomalidomide-induced liver injury. <i>Lancet</i> , The, 2014, 383, 2125-2126.	13.7	15
84	Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin's Lymphoma and Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 1714-1714.	1.4	7
85	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. <i>Blood</i> , 2014, 124, 3445-3445.	1.4	9
86	A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3486-3486.	1.4	3
87	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 395-395.	1.4	40
88	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 788-788.	1.4	1
89	Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype. <i>Blood</i> , 2013, 122, 3063-3063.	1.4	3
90	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. <i>Blood</i> , 2013, 122, 3760-3760.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Taking it up a notch in MCL. Blood, 2012, 119, 1957-1958.	1.4	2
92	Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial. Blood, 2012, 120, 3675-3675.	1.4	1
93	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. Blood, 2012, 120, 1875-1875.	1.4	0
94	SOX11 Directly Represses Wnt/ β -Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. Blood, 2012, 120, 895-895.	1.4	2
95	New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology, 2011, 21, 335-346.	9.6	35
96	A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma. Blood, 2011, 118, 441-441.	1.4	4
97	High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma. Blood, 2011, 118, 557-557.	1.4	1
98	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 779-779.	1.4	11
99	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	1.4	0
100	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 2010, 116, 1025-1034.	1.4	138
101	Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. Blood, 2010, 116, 436-436.	1.4	3
102	Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 435-435.	1.4	3
103	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. Blood, 2009, 114, 673-673.	1.4	0
104	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 874-882.	1.3	41
105	Epigenetic Determinants of Pathogenesis and Resistance to Proteasome Inhibition in Mantle Cell Lymphoma.. Blood, 2008, 112, 3373-3373.	1.4	8
106	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	1.4	117
107	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. Blood, 2006, 108, 225-225.	1.4	1
108	Human immunodeficiency virus-associated lymphoma. Clinical Advances in Hematology and Oncology, 2003, 1, 295-301.	0.3	6